

A fifth Xenia portfolio company obtains CE approval:

Medi-Tate Obtains CE Mark to Market its Product in Europe

Kiryat Gat, Israel – February 5, 2012 – Xenia Venture Capital (TASE: XENA) announced that its portfolio company Medi-Tate (in which Xenia holds 28.89%, fully diluted) which is developing a device for minimally invasive treatment of Benign Prostate Hyperplasia (BPH), has obtained CE approval to market its product in Europe. Medi-Tate is Xenia’s fifth portfolio company to obtain CE approval.

According to Anat Segal, CEO of Xenia, “We are happy that Medi-Tate has obtained the approval to market its device in Europe. This constitutes a significant milestone for the company and a major step towards the product’s commercialization. Our medical device portfolio is maturing, with five companies having obtained approvals to market their product in Europe and/or the US.

Anat Segal added: “2012 is looking like a year where quite a few of our companies will make major advances, creating value for shareholders.

As aforementioned, Medi-Tate joins a series of Xenia medical device portfolio companies which are authorized to market their products in Europe. Among them is Xenolith, which has developed an innovative urethroscopic system designed to prevent stone migration to the kidneys. Another one is Ortho-Space, which uses a biodegradable balloon technology for the treatment of shoulder rotator-cuff injuries. It was preceded by BioProtect, which uses the biodegradable balloon technology for tissue separation in radiation treatments of prostate cancer. Another Xenia portfolio company to obtain CE approval is NeatStitch, which has developed a medical device for internal automatic suturing for laparoscopic procedures entitled NeatClose. NeatStitch has also obtained FDA approval and is already marketing its products in the US.

About Medi-Tate

Medi-Tate, which was established in 2007, develops, produces and markets an alternative treatment for Benign Prostate Hyperplasia (BPH). The Company has developed an innovative medical device, which does not necessitate surgical intervention but yields results that are similar to it. The company’s product is applied without the need for hospitalization or general anaesthesia, which are necessary in surgical procedures. The company is conducting clinical trials in a number of medical centers in Europe and Israel.

About Xenia Venture Capital

Xenia Venture Capital (TASE: XENA) is a publically traded investment company which operates a privatized technological incubator. Xenia Venture Capital specializes in investments in companies and start-ups in the fields of medical devices and IT. Among Xenia’s founders and main shareholders are the Novacom Group and H. Mer Industries, Menorah Insurance Company, Dash Apex, Mivney Taasiya of the Fishman Group, Anat Segal (CEO), as well as leading high-tech figures. Xenia Ventures’ Board of Directors and Advisory Board comprise highly successful business entrepreneurs,



POWERHOUSE OF THE ENTREPRENEURS

members of Israel's high-tech elite, such as Mr. Haim Mer, Tal Menipaz, Dr. Orna Berry, Mr. Roni Einav, Mr. Aki Ratner, Mr. Gideon Mantel, Dr. Yafit Stark, Prof. Yossi Shaham, and others. Xenia's goal is to jump-start and support IT and medical device start ups so as to maximize their chances of success in world markets and enhance the realization of their business potential. Since its establishment at the end of 2003, Xenia Ventures has invested in more than twenty companies, many of which have completed follow-on investments and have gone on to launch their products in global markets, achieving sales and profitability and creating strategic partnerships with leaders in their fields. Leading IT portfolio companies include, among others, Correlix, Arcos, BandWD, Safepeak, Superfish, M-Photo, Intuview, and Playcast, SAManage, BookPulse, and Saguna.. In the medical devices field, Xenia has invested in BioProtect, NeatStitch, Medi-tate, ActiVein, Slimedics, and OrthoSpace, among others Please visit our website at: